Pfizer Korea's top-selling ethical products face strong challenge

Published: 2003-11-10 07:00:00

Updated: 2003-11-10 07:00:00

Pharmaceutical business sources say that Pfizer Korea's flagship products such as Norvasc (amlodipine besylate) and Lipitor (atorvastatin) is/will be grapping with fierce competition among competitors to carve out their domestic market share in the midst of deteriorating market conditions like sl...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK